MENU
WGO
Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
Follow
WGO: Facebook WGO: Twitter
Share

Eosinophilic Esophagitis: The Only Constant Thing is Change

Shahan Fernando, MD

Shahan Fernando, MD
Pediatric Gastroenterology Fellow; Section of Pediatric Gastroenterology,
Hepatology, and Nutrition
Digestive Health Institute; Children’s Hospital Colorado
Aurora, USA

   
Glenn T. Furuta, MD

Glenn T. Furuta, MD
Professor of Pediatrics; University of Colorado School of Medicine
Director, Gastrointestinal Eosinophilic Diseases Program; Attending
Physician; Digestive Health Institute; Children’s Hospital
Colorado; National Jewish Health; Aurora, USA

Over the last three decades, the clinicopathological entity eosinophilic esophagitis (EoE) has emerged as a “new” disease, a disease that is now recognized as one of the major causes of feeding problems in children and of dysphagia and food impaction in adults. Although well-defined patients with EoE were originally reported by Attwood and Straumann in the early 1990s, only recently has the clinical importance of this disease been fully appreciated 1, 2. Evidence of this dramatic change is the rapid increase in publications on this disease; a PubMed search of “eosinophilic esophagitis” or “eosinophilic oesophagitis” reveals that ¾ of the over 1,000 articles in PubMed have been published since 2007 when the original EoE Consensus Recommendations were written 3. We refer the reader to a number of recently published reviews from across the world that fully detail many of the salient features of this disease and its treatment 4-15. Here we present a brief review of important clinical points, identify key differences of this disease between children and adults, relate factors influencing the epidemiology of the disease, share potential relationships that this disease shares with other clinical phenotypes of esophageal eosinophilia, and raise areas of clinical needs that require further investigation.

A dynamic disease with many faces

The intense proliferation of literature since the initial descriptions, and the publication of two Consensus Recommendations 3, 16 and a Clinical guideline 17, provides proof that the scientific and clinical understanding of EoE continue to develop at a rapid pace. Research studies and clinical experiences determined that EoE is a clinicopathological disease requiring both symptoms and abnormal histology to make the diagnosis. Children may present with a wide array of non-specific symptoms including the gradual onset of feeding problems or intermittent  episodes of vomiting and abdominal pain; these common problems are often mistaken for GERD and typically do not respond to GERD  treatments. Adults present with either solid food dysphagia or food impactions, symptoms that demand identification of an underlying etiology. A number of studies have now shown that EoE is one of the most common underlying etiologies of food impaction. In addition, because of the chronic nature of the disease, children and adults may have developed “coping” behaviors to adapt to their esophageal dysfunction; these behaviors may be missed, as they require additional questioning during the clinical history. Prolonged mealtimes, excessive chewing, avoidance of meats, breads or highly textured foods, and regular use of copious amounts of water or lubricating agents to swallow are not uncommon symptoms that often require elicitation. Endoscopic findings are not pathognomonic and include esophageal rings, furrows, exudates, longitudinal tearing, and strictures. (See Figure 1.) The latter finding may not be evident at the time of endoscopy and require an esophagram to detect. Histologically, the disease is characterized by dense esophageal eosinophilia and marked evidence of epithelial regeneration with basal cell hyperplasia and rete pege elongation. (See Figure 2.) Other causes of esophageal eosinophilia need to be ruled out before assigning a diagnosis of EoE. The natural history of EoE is not fully understood. While EoE is a chronic inflammatory disease, it does not carry  pre-malignant potential; strictures and food impactions can occur, but not all EoE patients appear to develop these complications. Treatments include dietary exclusions of food allergens, topical steroids and esophageal dilation.

 

Figure 1: Endoscopic appearance of eosinophilic esophagitis: Mucosal evidence of active inflammation with white exudates, linear furrows and loss of vascular pattern.

 

Figure 2: Histological appearance of eosinophilic esophagitis: Representative section of squamous epithelia with dense eosinophilic inflammation, superficial layering of eosinophils, rete pege elongation and basal cell hyperplasia. (Figure courtesy of Kelley Capocelli, M.D.)

An allergic / Th2 immunomicromilieu characterizes the esophageal mucosa

Ongoing and past research supports the tenet that EoE occurs when the genetically pre-disposed host encounters an allergic trigger, leading to the production of eosinophil chemokines in the esophageal mucosa, and ultimately driving mucosal eosinophilia. In this regard, gene array and genome wide association studies have identified at least four key molecules strongly associated with EoE. Thymic Stromal Lymphopoietin (TSLP) activates dendritic cells to promote Th2 cell responses, facilitates IgE production, and promotes expansion of basophils; this molecule likely plays a key role in other allergic inflammatory disease such as eczema and asthma. Eotaxin-3 is a potent eosinophil chemoattractant that is increased in EoE patients and when knocked out in animal models, esophageal eosinophilia is diminished. Il-5 and Il-13 play key roles in other atopic diseases and have been shown to participate in EoE in in vitro, in vivo, and translational EoE models. Together, identification of these inflammatory molecules has increased our understanding of the pathogenesis of this disease and points us toward potential future therapeutic targets.

Similarities and differences between children and adults

Whether clinical and histological features identified in children and adults represent a continuum that define the natural history of this inflammatory disease or children and adults manifest two different phenotypes is not fully agreed upon 12. Because of developmental differences, children may not be able to fully report symptoms such as dysphagia, thus leading to feeding problems as a primary manifestation. Endoscopic features representative of acute inflammation such as furrows and exudate, appear to be more common in children, whereas those suggestive of chronic inflammation such as rings, strictures, and tears may be more common in adults. While this appears to be a trend, these findings are not exclusively seen in one age group. Histologically, eosinophils remain the hallmark and biomarker of EoE; other features indicative of remodeling and chronic injury have not been definitively shown to be more common in adults or children. Therapeutic efficacies of treatments, whether diet, drug or dilation, do not appear to be different between children or adults, but the adherence to dietary exclusions may be more challenging in older patients.

A rapidly changing epidemiology

A number of studies suggest an incidence of EoE of 4 in 10,000 persons. Two observations have consistently emerged regarding the epidemiology of EoE. The first is that regardless of the study, EoE occurs more often in males. The second is that while EoE was once thought to occur primarily in Caucasians in academic centers in the industrialized countries, the scope of this disease clearly continues to expand. Over the last 5 years, case series and prospective studies report clinical experiences with EoE in urban and rural environments, ethnically diverse settings, and an expanding number of countries. Case series from China (proposed incidence/prevelance-0.34%), Saudi Arabia (0.85%), Ireland (0.1%), Korea (6.6%), and Mexico (4%) highlight this geographic variability. Since there is no known mortality associated with EoE and given its chronic nature, it is not surprising that its prevalence is increasing worldwide. Soon et al. recently published a systematic review with meta-analysis demonstrating geographic variations in pediatric population-based incidence and prevalence rates 18.

The chronic nature of EoE is emphasized by several recent studies. The majority (73%) of patients identified with pediatric esophageal eosinophilia had persistent symptoms into adulthood, as well as worse quality of life scores 15 years after the initial diagnosis 19. Additionally, the majority of those patients transitioned to the care of adult gastroenterologists due to esophageal food impactions (40%) and need for endoscopic dilation (14%) from esophageal stricture formation 20.

Several factors may indeed contribute to the increasing prevalence of this disease, such as increasing awareness and recognition of the clinicopathologic characteristics of EoE and increasing procurement of esophageal biopsies 21. Since genes do not change within a few decades, introduction of an environmental factor as a key co-factor in the development of this disease has also been strongly suspected. One speculation is that exogenous exposure of the esophagus to something that breaks the epithelial barrier may allow the underlying pre-disposed Th2 immunomilieu to become activated, thus leading to liberation of eosinophil chemotaxins and resultant eosophageal eosinophilia. This supposition leads one to wonder what these ingested barrier-breaking factors might be and whether they are related to the emerging nature of this disease in locales with changing diets and lifestyles that may predispose to ingesting these products.

Is it eosinophilic esophagitis, proton pump inhibitor responsive esophageal eosinophilia, or gastroesophageal reflux disease?

With the expanding recognition of esophageal eosinophilia as a histological finding has also come recognition of several other phenotypes that may or may not be pathophysiologically linked. For instance, since the diagnosis of EoE hinges on exclusion of other causes of esophageal eosinophilia, subgroups of patients have been recognized who present clinically as if they have EoE (dysphagia/food impaction), have very dense esophageal eosinophilia (> 15 per HPF), and who clinically and histologically respond to proton pump inhibition. Initially, these patients were thought to have GERD, but as molecular evidence supports an alternative antiinflammatory mechanism of action for PPIs, the term PPI-responsive esophageal eosinophilia (PPIREE) has arisen 22-25. To add further confusion to these observations is the finding that the clinicopathological effect of PPIs may not be sustained over time 26, 27. Whether these groups of patients represent a phenotype of GERD with an exuberant esophageal eosinophilia, EoE that responds to the anti-inflammatory actions of a PPI, or something else is not yet certain.  Molecular phenotyping of well-characterized patients, detailed histological descriptions of the esophageal topography as well as clinical  responses to therapeutic agents will provide more insights to these questions in the coming years.

Increasing number of questions worldwide

With the increased recognition of EoE across the world, a number of questions arise that will not only immediately improve the quality of life of patients with EoE, but also potentially identify novel therapeutic targets. What unique dietary or environmental factors contribute to or prevent the development of EoE? Do genetic patterns remain constant throughout the world? What other clinical phenotypes will be recognized as the natural history of EoE is documented? Careful observations and analyses of patients with esophageal eosinophilia, and answers to these and other questions, will continue to change the face of this fascinating disease.

References

  1. Attwood S, Smyrk T, Demeester T, Jones J. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993;38:109-116.
  2. Straumann A, Spichtin HP, Bernoulli R, Loosli J, Vogtlin J. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. Schweiz Med Wochenschr 1994;124:1419-29.
  3. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-63.
  4. Vashi R, Hirano I. Diet therapy for eosinophilic esophagitis: when, why and how. Current opinion in gastroenterology 2013;29:407-15.
  5. Rodrigues M, D’Amico MF, Patino FR, Barbieri D, Damiao AO, Sipahy AM. Clinical manifestations, treatment, and outcomes of children and adolescents with eosinophilic esophagitis. Jornal de pediatria 2013;89:197-203.
  6. Murch SH, Allen K, Chong S, Dias JA, Papadopoulou A. Potential for Improving Therapy and Defining New Research Targets in Eosinophilic Oesophagitis Based on Understanding of Immunopathogenesis. Journal of Pediatric Gastroenterology and Nutrition 2013 in press.
  7. Lucendo AJ, Arias A, Molina-Infante J, Rodriguez-Sanchez J, Rodrigo L, Nantes O, Perez-Arellano E, de la Riva S, Perez-Aisa A, Barrio J. Diagnostic and therapeutic management of eosinophilic oesophagitis in children and adults: Results from a Spanish registry of clinical practice. Digestive and liver disease 2013;45:562-8.
  8. Dellon ES. Eosinophilic esophagitis. Gastroenterology clinics of North America 2013;42:133-53.
  9. Davis CM. Practical management of eosinophilic esophagitis. Pediatric Annals 2013;42:128-34.
  10. Davis BP, Rothenberg ME. Emerging concepts of dietary therapy for pediatric and adult eosinophilic esophagitis. Expert Rev Clin Immunol 2013;9:285-7.
  11. Straumann A, Schoepfer AM. Therapeutic concepts in adult and paediatric eosinophilic oesophagitis. Nature reviews-Gastroenterolo Hepatol 2012;9:697-704.
  12. Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I, Schoepfer AM, Simon D, Simon HU. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy 2012;67:477-90.
  13. Shaffer CC, Ghaffari G. International survey on evaluation and management of eosinophilic esophagitis. World Allergy Organization J 2012;5:95-102.
  14. Lieberman JA, Chehade M. Eosinophilic esophagitis: diagnosis and management. Immunol Clin NA 2012;32:67-81.
  15. Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:1066-78.
  16. Liacouras CA FG, Hirano I, Atkins D, Attwood S, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SS, Spechler S, Spergel JM, Straumann A, Wershil BK, Rothenberg ME, Aceves S. Eosinophilic Esophagitis: Updated Consensus Recommendations for Children and Adults. J All Clin Immunol 2011;1283-20.
  17. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA. ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). Amer J Gastroenterol; 2013;108:679-92.
  18. Soon IS, Butzner JD, Kaplan GG, Debruyn JC. Incidence and prevalence of eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr 2013;57:72-80.
  19. DeBrosse CW, Franciosi JP, King EC, Butz BK, Greenberg AB, Collins MH, Abonia JP, Assa’ad A, Putnam PE, Rothenberg ME. Long-term outcomes in pediatric-onset esophageal eosinophilia. J All Clin Immunol 2011;128:132-8.
  20. Menard-Katcher P, Marks KL, Liacouras CA, Spergel JM, Yang YX, Falk GW. The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood. Aliment Pharm Ther 2013;37:114-21.
  21. Syed AA, Andrews CN, Shaffer E, Urbanski SJ, Beck P, Storr M. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Aliment Pharm Ther 2012;36:950-8.
  22. Hirano I. Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again. Clin Gastro Hepatol 2011;9:99-101.
  23. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 2009;137:1776-84.
  24. Zhang X, Cheng E, Huo X, Yu C, Zhang Q, Pham TH, Wang DH, Spechler SJ, Souza RF. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PloS one 2012;7:e50037.
  25. Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang DH, Spechler SJ, Souza RF. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 2013;62:824-32.
  26. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci 2012;57:1413-9.
  27. Schroeder S, Capocelli KE, Masterson JC, Harris R, Protheroe C, Lee JJ, Furuta GT. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2013;56:166-72.